Default company panoramic image

PlantForm Corporation

PlantForm is commercializing a platform for manufacturing therapeutic drugs at ultra low cost using plants as the production sytem.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Canada
  • Currency USD
  • Founded April 2008
  • Employees 15
  • Website

Company Summary

PlantForm is a Canadian biotechnology company with a focus on low cost production of therapeutic drugs. PlantForm has licensed the rights to a technology for the manufacture of biological drugs in tobacco plants from the University of Guelph and is establishing the commercial applications of the platform for biosimilar antibodies (Herceptin and others); for HIV/AIDS antibodies; and for a therapeutic enzyme (funded by US Government).


  • Default avatar
    Don Stewart

    Dr. Don Stewart is an entrepreneur and scientist with more than 20 years of management experience in the biotechnology industry. Dr. Stewart served as Director Research of Cangene Corporation from 1997 to 2007. At Cangene, he led programs to develop monoclonal antibodies and recombinant protein drugs and obtained more than $15 million in external grant and contract funding over a five-year period. Dr. Stewart has a PhD in biochemistry from the U

  • Default avatar
    Ron Hosking

    Mr. Hosking is a chartered accountant with three decades of experience as a financial manager in the biotechnology and pharmaceutical industries. From 1997 to 2008, Mr. Hosking was Vice-President Finance & Chief Financial Officer for PreMD Inc., a developer of point-of-care medical devices. He guided the company through seven public financings and onto the TSX (2000) and AMEX (2002) stock exchanges. He also helped negotiate out-licensing partner

  • Default avatar
    Chris Hall

    Dr. Chris Hall is a professor and Canada Research Chair in Recombinant Antibody Technology at the University of Guelph. As a Tier 1 Canada Research Chair since 2002, Dr. Hall is acknowledged as a world leader in his field. His research focuses on producing antibodies from plants (instead of animals) for a range of applications, including human immunotherapy. Dr. Hall's research group also studies the large-scale production of antibodies in plant

  • Default avatar
    David Cayea

    Mr. David Cayea is an entrepreneur with more than 14 years of experience in the successful start-up of private sector companies in multiple industries. He has extensive business management experience in Europe, Asia and North America, most recently as the founder and CEO of North American Safety Consultants, based in Abu Dhabi, United Arab Emirates. David has a Bachelor of Arts degree from Brock University in Environmental Studies and Politics as


  • Default avatar
    David Pamenter, Gowling Lafleur Henderson LLP, Toronto, Canada
    Default avatar
    BDO Dunwoody, Toronto, Canada

Previous Investors

  • Default avatar
    Atlantic Assets Trust, UK
    Default avatar
    York Medtech Partners Inc., Canada
    Default avatar
    Angels and Founders